Merck on Thursday said its experimental treatment designed to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial, bringing the company one step clo… [+2749 chars]Read More
Merck says experimental RSV treatment protected infants in trial paving way for potential approval CNBC
